Targeting Drug-Metabolizing Enzymes for Effective Chemoprevention and Chemotherapy
Open Access
- 16 March 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 38 (4), 539-544
- https://doi.org/10.1124/dmd.109.031351
Abstract
The primary focus of chemoprevention research is the prevention of cancer using pharmacological, biological, and nutritional interventions. Chemotherapeutic approaches that have been used successfully for both the prevention and treatment of a number of human malignancies have arisen from the identification of specific agents and appropriate molecular targets. Although drug-metabolizing enzymes have historically been targeted in attempts to block the initial, genotoxic events associated with the carcinogenic process, emerging evidence supports the idea that manipulating drug-metabolizing enzymes may also be an effective strategy to be used for treating tumor progression, invasion, and, perhaps, metastasis. This report summarizes a symposium that presents some recent progress in this area. One area of emphasis is the development of a CYP17 inhibitor for treatment of prostate cancer that may also have androgen-independent anticancer activity at higher concentrations. A second focus is the use of a mouse model to investigate the effects of aryl hydrocarbon receptor and Cyp1b1 status and chemopreventative agents on transplacental cancer. A third area of focus is the phytochemical manipulation of not only cytochrome P450 (P450) enzymes but also phase II inflammatory and antioxidant enzymes via the nuclear factor-erythroid 2-related factor 2 pathway to block tumor progression. A final highlight is the use of prodrugs activated by P450 enzymes to halt tumor growth and considerations of dosing schedule and targeted delivery of the P450 transgene to tumor tissue. In addition to highlighting recent successes in these areas, limitations and areas that should be targeted for further investigation are discussed.Keywords
This publication has 26 references indexed in Scilit:
- Anti-NF-κB and anti-inflammatory activities of synthetic isothiocyanates: Effect of chemical structures and cellular signalingChemico-Biological Interactions, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Human Telomerase Reverse Transcriptase Promoter-Driven Oncolytic Adenovirus with E1B-19 kDa and E1B-55 kDa Gene DeletionsHuman Gene Therapy, 2008
- Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transferCancer Gene Therapy, 2008
- Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancerMolecular Cancer Therapeutics, 2008
- Fetal MouseCyp1b1and Transplacental Carcinogenesis from Maternal Exposure to Dibenzo(a,l)pyreneCancer Prevention Research, 2008
- Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinibMolecular Cancer Therapeutics, 2008
- Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy modelCancer Gene Therapy, 2007
- Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug developmentBioorganic & Medicinal Chemistry, 2007
- Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancerSteroids, 2006